Acorda to Host Conference Call to Discuss Fourth Quarter and Year End 2015 Results on February 11, 2016
January 28 2016 - 7:00AM
Business Wire
Acorda Therapeutics, Inc. (Nasdaq:ACOR) will
host a conference call and webcast to report its fourth quarter and
year end 2015 financial results and pipeline updates on Thursday,
February 11 at 8:30 a.m. ET.
To participate in the conference call, please
dial (855) 542-4209 (domestic) or (412) 455-6054 (international)
and reference the access code 37655218. The presentation will be
available via a live webcast on the Investors section of
www.acorda.com. Please log in approximately 5 minutes before the
scheduled time of the presentation to ensure a timely
connection.
A replay of the call will be available from
1:30 p.m. ET on February 11, 2016 until 11:59 pm on February 18,
2016. To access the replay, please dial (855) 859-2056 (domestic)
or (404) 537-3406 (international) and reference the access code
37655218. The archived webcast will be available in the Investor
Relations section of the Acorda website at www.acorda.com.
About Acorda Therapeutics
Founded in 1995, Acorda
Therapeutics is a biotechnology company focused on developing
therapies that restore function and improve the lives of people
with neurological disorders.
Acorda has an industry leading pipeline of
novel neurological therapies addressing a range of disorders,
including multiple sclerosis, Parkinson’s disease, post-stroke
walking deficits, epilepsy and migraine. Acorda markets
three FDA-approved therapies, including AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg.
For more information, please visit the
Company’s website at: www.acorda.com.
Forward-Looking Statement
This press release includes forward-looking
statements. All statements, other than statements of historical
facts, regarding management's expectations, beliefs, goals, plans
or prospects should be considered forward-looking. These statements
are subject to risks and uncertainties that could cause actual
results to differ materially, including: the ability to complete
the Biotie transaction on a timely basis or at all; the ability to
realize the benefits anticipated from the Biotie and Civitas
transactions, among other reasons because acquired development
programs are generally subject to all the risks inherent in the
drug development process and our knowledge of the risks
specifically relevant to acquired programs generally improves over
time; the ability to successfully integrate Biotie’s operations and
Civitas’ operations, respectively, into our operations; we may need
to raise additional funds to finance our expanded operations and
may not be able to do so on acceptable terms; our ability to
successfully market and sell Ampyra in the U.S.; third party payers
(including governmental agencies) may not reimburse for the use of
Ampyra or our other products at acceptable rates or at all and may
impose restrictive prior authorization requirements that limit or
block prescriptions; the risk of unfavorable results from future
studies of Ampyra or from our other research and development
programs, including CVT-301, Plumiaz, or any other acquired or
in-licensed programs; we may not be able to complete development
of, obtain regulatory approval for, or successfully market CVT-301,
Plumiaz, any other products under development, or the products that
we would acquire if we complete the Biotie transaction; the
occurrence of adverse safety events with our products; delays in
obtaining or failure to obtain and maintain regulatory approval of
or to successfully market Fampyra outside of the U.S. and our
dependence on our collaboration partner Biogen in connection
therewith; competition; failure to protect our intellectual
property, to defend against the intellectual property claims of
others or to obtain third party intellectual property licenses
needed for the commercialization of our products; and failure to
comply with regulatory requirements could result in adverse action
by regulatory agencies.
These and other risks are described in greater
detail in our filings with the Securities and Exchange
Commission. We may not actually achieve the goals or plans
described in our forward-looking statements, and investors should
not place undue reliance on these statements. Forward-looking
statements made in this release are made only as of the date
hereof, and we disclaim any intent or obligation to update any
forward-looking statements as a result of developments occurring
after the date of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160128005171/en/
Acorda TherapeuticsFelicia Vonella,
914-326-5146fvonella@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2023 to Apr 2024